Company Filing History:
Years Active: 2008
Title: Wayne Robert Hein: Innovator in Monoclonal Antibody Research
Introduction
Wayne Robert Hein is a notable inventor based in Wellington, New Zealand. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on addressing nematode infections, which pose challenges in both agricultural and medical contexts.
Latest Patents
Wayne Robert Hein holds a patent for an isolated monoclonal antibody known as mAb PAB-1. This antibody, deposited at the American Type Culture Collection (ATCC) on January 24, 2002, is assigned accession number PTA-4005. The invention relates to the binding of this monoclonal antibody to a surface antigen on nematode L3 larvae. Additionally, it encompasses the antigen that interacts with the monoclonal antibody and outlines its applications in diagnosing, treating, or preventing nematode infections.
Career Highlights
Wayne is associated with Ovita Limited, a company that focuses on innovative solutions in the agricultural sector. His work at Ovita Limited has allowed him to contribute to advancements in biotechnology and improve methods for managing nematode-related challenges.
Collaborations
Wayne Robert Hein has collaborated with notable colleagues, including Gavin Bernard Lear Harrison and Hugh Douglas Pulford. These partnerships have fostered a collaborative environment that enhances research and development efforts in their field.
Conclusion
Wayne Robert Hein's contributions to monoclonal antibody research exemplify the impact of innovation in biotechnology. His patent and work at Ovita Limited highlight the importance of addressing nematode infections through scientific advancements.